BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27906162)

  • 1. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.
    Eriksson E; Moreno R; Milenova I; Liljenfeldt L; Dieterich LC; Christiansson L; Karlsson H; Ullenhag G; Mangsbo SM; Dimberg A; Alemany R; Loskog A
    Gene Ther; 2017 Feb; 24(2):92-103. PubMed ID: 27906162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
    Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
    J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
    Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
    Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
    Wang Q; Yang M; Zhang Y; Zhong L; Zheng X
    Curr Gene Ther; 2019; 19(1):54-65. PubMed ID: 30848201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
    Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
    Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
    Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
    Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L.
    Liu GY; Li ZJ; Li QL; Jin Y; Zhu YH; Wang YH; Liu MY; Li YG; Li Y
    Int Immunopharmacol; 2015 Sep; 28(1):487-93. PubMed ID: 26208317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
    Kikuchi T; Moore MA; Crystal RG
    Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma.
    Serba S; Schmidt J; Wentzensen N; Ryschich E; Märten A
    Gut; 2008 Mar; 57(3):344-51. PubMed ID: 17675324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.
    Dotti G; Savoldo B; Takahashi S; Goltsova T; Brown M; Rill D; Rooney C; Brenner M
    Exp Hematol; 2001 Aug; 29(8):952-61. PubMed ID: 11495701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
    Sin JI; Kim JJ; Zhang D; Weiner DB
    Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
    Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
    Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
    Liu Y; Qureshi M; Xiang J
    Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells.
    Kikuchi T; Crystal RG
    Hum Gene Ther; 1999 May; 10(8):1375-87. PubMed ID: 10365667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.
    Liljenfeldt L; Dieterich LC; Dimberg A; Mangsbo SM; Loskog AS
    Cancer Gene Ther; 2014 Mar; 21(3):95-102. PubMed ID: 24481488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.
    Loskog A; Dzojic H; Vikman S; Ninalga C; Essand M; Korsgren O; Totterman TH
    J Immunol; 2004 Jun; 172(11):7200-5. PubMed ID: 15153545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
    Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
    Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.